Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kaken Pharmaceutical Co., Ltd. (4521.T)
Tokyo, JP
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.42% | +2.59% | +0.60% | -1.42% | +13.80% | +3.74% | +10.98% | +12.87% | -7.65% | -28.44% | +228.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-18.3% Q1'26: +6.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-84.5% Q1'26: +114.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-5.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1.2% Q1'26: -7.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-0.8% Q1'26: -5.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.7% ★ Q1'26: -2.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.59× ★ Q1'26: -2.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
93.90B
est: 93.90B (0.0%)
|
109.22B
est: 109.95B (-0.7%)
|
101.99B
est: 102.85B (-0.8%)
|
98.43B
est: 99.75B (-1.3%)
|
94.17B
est: 92.60B (+1.7%)
|
89.23B
est: 89.50B (-0.3%)
|
74.98B
est: 76.90B (-2.5%)
|
76.03B
est: 76.00B (+0.0%)
|
72.98B
est: 71.50B (+2.1%)
|
72.04B
est: 72.70B (-0.9%)
|
94.04B
est: 90.55B (+3.8%)
|
82.17B
79.18B – 85.29B
-9.3% YoY
|
74.16B
71.03B – 75.78B
-9.7% YoY
|
78.25B
75.86B – 82.49B
+5.5% YoY
|
88.00B
84.28B – 91.73B
+12.5% YoY
|
97.90B
94.34B – 101.62B
+11.3% YoY
|
| EBITDA |
23.03B
est: 19.40B (+18.7%)
|
37.39B
est: 22.71B (+64.6%)
|
32.64B
est: 21.25B (+53.6%)
|
29.91B
est: 20.61B (+45.1%)
|
27.19B
est: 19.13B (+42.1%)
|
29.37B
est: 18.49B (+58.9%)
|
20.99B
est: 15.89B (+32.1%)
|
16.38B
est: 15.70B (+4.4%)
|
9.40B
est: 14.77B (-36.3%)
|
12.57B
est: 15.02B (-16.3%)
|
22.02B
est: 18.71B (+17.7%)
|
16.97B
16.36B – 17.62B
-9.3% YoY
|
15.32B
14.67B – 15.65B
-9.7% YoY
|
16.17B
15.67B – 17.04B
+5.5% YoY
|
18.18B
17.41B – 18.95B
+12.5% YoY
|
20.22B
19.49B – 20.99B
+11.2% YoY
|
| EBIT |
20.63B
est: 16.32B (+26.4%)
|
35.15B
est: 19.10B (+84.0%)
|
30.71B
est: 17.87B (+71.8%)
|
27.71B
est: 17.33B (+59.8%)
|
24.59B
est: 16.09B (+52.8%)
|
26.51B
est: 15.55B (+70.5%)
|
18.67B
est: 13.36B (+39.8%)
|
13.90B
est: 13.21B (+5.3%)
|
6.83B
est: 12.42B (-45.0%)
|
9.81B
est: 12.63B (-22.3%)
|
19.47B
est: 15.73B (+23.7%)
|
14.28B
13.76B – 14.82B
-9.3% YoY
|
12.89B
12.34B – 13.17B
-9.7% YoY
|
13.60B
13.18B – 14.33B
+5.5% YoY
|
15.29B
14.64B – 15.94B
+12.5% YoY
|
17.01B
16.39B – 17.66B
+11.3% YoY
|
| Net Income |
12.12B
est: 11.19B (+8.3%)
|
21.14B
est: 19.21B (+10.0%)
|
22.02B
est: 19.70B (+11.8%)
|
19.04B
est: 18.72B (+1.7%)
|
17.78B
est: 15.40B (+15.4%)
|
19.37B
est: 17.82B (+8.7%)
|
13.41B
est: 13.31B (+0.7%)
|
9.55B
est: 9.28B (+2.8%)
|
5.44B
est: 10.96B (-50.4%)
|
8.03B
est: 7.62B (+5.3%)
|
13.95B
est: 16.46B (-15.3%)
|
2.60B
2.48B – 2.73B
-84.2% YoY
|
1.67B
1.52B – 1.82B
-35.8% YoY
|
2.35B
1.52B – 3.70B
+40.6% YoY
|
3.07B
2.99B – 4.23B
+30.5% YoY
|
5.44B
5.18B – 5.71B
+77.4% YoY
|
| SGA |
20.59B
est: 19.85B (+3.7%)
|
20.30B
est: 23.24B (-12.6%)
|
20.02B
est: 21.74B (-7.9%)
|
20.17B
est: 21.08B (-4.3%)
|
18.72B
est: 19.57B (-4.3%)
|
17.32B
est: 18.92B (-8.4%)
|
16.16B
est: 16.25B (-0.6%)
|
15.83B
est: 16.06B (-1.4%)
|
15.48B
est: 15.11B (+2.4%)
|
16.17B
est: 15.37B (+5.2%)
|
18.50B
est: 19.14B (-3.3%)
|
17.37B
16.74B – 18.03B
-9.3% YoY
|
15.68B
15.01B – 16.02B
-9.7% YoY
|
16.54B
16.04B – 17.44B
+5.5% YoY
|
18.60B
17.81B – 19.39B
+12.5% YoY
|
20.69B
19.94B – 21.48B
+11.2% YoY
|
| EPS |
290.90
est: 293.18 (-0.8%)
|
510.54
est: 503.47 (+1.4%)
|
536.70
est: 516.12 (+4.0%)
|
470.55
est: 490.65 (-4.1%)
|
445.78
est: 403.55 (+10.5%)
|
494.89
est: 466.84 (+6.0%)
|
347.37
est: 348.73 (-0.4%)
|
251.44
est: 243.30 (+3.3%)
|
144.79
est: 288.20 (-49.8%)
|
212.66
est: 197.90 (+7.5%)
|
365.42
est: 430.74 (-15.2%)
|
68.12
64.90 – 71.48
-84.2% YoY
|
44.00
39.78 – 47.77
-35.4% YoY
|
65.72
39.79 – 96.84
+49.4% YoY
|
94.50
78.27 – 110.73
+43.8% YoY
|
142.50
135.77 – 149.55
+50.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.05% | 282.4K | 0.58% |
| 2 | iShares MSCI Japan Small-Cap ETF SCJ | 0.04% | 114.4K | 0.50% |
| 3 | Schwab Fundamental International Small Company Index ETF FNDC | 0.03% | 961.7K | 0.39% |
| 4 | Schwab International Small-Cap Equity ETF SCHC | 0.03% | 1.53M | 0.06% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.68M | 0.06% |
| 6 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 42.3K | 0.83% |
| 7 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.02% | 2.55M | 0.40% |
| 8 | Amundi Japan TOPIX II UCITS ETF EUR Hedged Dist JPNH.PA | 0.01% | 88.6K | 0.45% |
| 9 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.01% | 87.1K | 0.45% |
| 10 | iShares Core MSCI Japan IMI UCITS ETF IJPA.L | 0.01% | 940.7K | 0.12% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroyuki Horiuchi | Chairman, President & Representative Director | 103M | male |
| Hideki Kawabata | Head of Clinical Development Department | — | — |
| Keizo Kimura | Corporate Officer, Chief Officer of Production Division & Chief of Shizuoka Factory | — | male |
| Masaru Ogawa | Chief Officer of Regulatory Affairs Division & GM of Regulatory Affairs Department | — | — |
| Masashi Suzudo | MD, Director of the Corporate Planning & Coordination Department and Director | — | male |
| Mitsuru Watanuki | Chief Officer of R&D Division and Director | — | male |
| Tatsuhiro Harada | Deputy Chief Officer of R&D Division & Chief of Drug Research Center | — | — |
| Tomohiro Takaya | General Manager of Legal Affairs & Intellectual Property Department | — | male |
| Gaku Kametsu | General Manager of Corporate Communications Department | — | — |
| Tomoyuki Koseki | Chief Officer of Marketing & Sales Division | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4521.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
